Proprietary Pb-Chelation Technology
Binding Lead with High Affinity
Perspective Therapeutics' proprietary Lead Specific Chelator (PSC) is used to securely bind and conjugate radioactive isotopes of Lead (Pb) to cancer-targeted peptides.
Chelators are organic molecules that bind to metal ions with high affinity. They act as chemical cages in radiopharmaceuticals by encapsulating and anchoring the radioisotope to targeting molecules. Traditional chelators, such as DOTA, have served as the backbone for numerous applications in nuclear medicine due to their availability and broad utility. However, they are limited when it comes to their binding capacities for certain radioisotopes, such as lead.
Perspective Therapeutics has engineered a novel chelator designed especially for lead isotopes, called PSC. Our PSC not only exhibits high affinity for lead but also maintains a net neutral charge which supports rapid renal clearance. This unique combination allows for lead and its daughters bismuth to be firmly anchored without leakage, which offers significant improvements over DOTA and other widely used chelators. The advantages include increased targeting precision of the radiation, reduced off-target accumulation, and enhanced clearance rates, which collectively contribute to better patient outcomes and reduced side effects.
Chelator binding the isotope.
